Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
mETH Protocol will gradually cease the operation of cmETH, and the reward claiming window will close on November 7.

mETH Protocol will gradually cease the operation of cmETH, and the reward claiming window will close on November 7.

ForesightNewsForesightNews2026/05/07 14:42
Show original

Foresight News reported that mETH Protocol has officially announced it will gradually discontinue the operation of its liquidity re-staking token cmETH, while other products will continue to operate as usual. The cmETH minting function was closed on May 7, 2026, and the final EigenLayer reward distribution will be completed in mid-June 2026. The reward claim window will close on November 7, 2026.


mETH Protocol stated that, after comprehensively evaluating current market developments, discontinuing cmETH is the most prudent choice, allowing resources to be refocused on directions that can create more lasting value for users. Existing holdings are not affected, while the unstaking and bridging functions remain available.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.

Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.

智通财经2026/09/24 06:51

Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

智通财经2026/09/24 06:51
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

Australian stocks closed down 0.72%

格隆汇2026/09/24 06:27